There are multiple definitions of biochemical recurrence for prostate cancer treatment post surgery. This causes confusion both within the patient community and the medical community. It would be very helpful if we could standardize a simple measure, PSA as the biomarker for a biochemical recurrence. Standardization post surgery would give us a better way to [...]
Historically, too many men were haphazardly treated for prostate cancer. Happily, the incidents of over treatment have been declining and the general acceptance of Active Surveillance has emerged as the preferred management strategy for men with very low–risk prostate cancer. However, There is still too few high-quality comparative effectiveness studies evaluating the incremental risks associated [...]
We have a number of newer hormone pathway drugs now available to treat men with metastatic castrate resistant prostate cancer (mCRPC). Researchers have shown that prostate specific antigen (PSA) response can be used as a pharmaco-dynamic end-point that may help identify men with early resistance to these new drugs. They found that there is clinical [...]
Making treatment decisions once you have been diagnosed with prostate cancer is difficult. Often, it is impossible to accurately and reliably be able to predict the eventual course of the cancer. Prostate cancer, besides being one of the slower growing cancers, is also one of the deadliest. So good, informed decisions are vital. The original [...]
Not often discussed, but a valuable measure of prostate cancer bone activity is serum (in the blood) alkaline phosphatase. It is a normal enzyme produced naturally by the body. Everyone produces some of this enzyme regardless of his or her state of health, gender, or age. The tissues that produce the most alkaline phosphatase are the [...]